Ceapro Inc V.CZO

re;REITREDCEO2016....is that You OATS ?...wink/wink....

[ISAloser247]

$1.00 in Days ?

[Retiredceo2016]

As I indicated - 2 good quarterly financial releases continuing the positive trend will move the stock price. First back to the 80 cent range and then over $1....give it 6 months! 

[prophetoffactz]

Those focused on the financial results may be disappointed. This company is transitioning to a biopharma and it will have associated clinical trial costs and the costs of scaling up PGX. This story is increasingly about the pipeline which has key catalysts in 2023.  Q4 is also usually CZO's weakest quarter. On an annual basis, however, the annual results typically presented in April

[Ciao]

Spot on, financials will not be great, they are good enough to support the R&D pipeline development. Catalysts for the stock that could help sustain a move would be an out-licensing deal or some partnership announcement.The market will look for the next deal once the first is announced. That first deal will be the commercial validation of PGX that we have been waiting for. It's good to

[prophetoffactz]

All that said the base businss could surprise. The Symrise deal was expected to potentially accelerate sales and the hunt for new opportunities will be one year in. CZO's new CMO is also on the hunt for new opportunities. Gilles talked about opportunities in the Small Cap Discoveries interview. There are also new market opportunities like Japan. Symrise is focused on cosmetics and

[prophetoffactz]

One thing we haven't heard about is the cannabis line. Development and launch of the CBD line for medical use was expected in 2022. Maybe that will come with a re-launch of JuventeDC more generally. The chaos from COVID had shelved that product but things have normalized. 

[Retiredceo2016]

As I indicated - 2 good quarterly financial releases continuing the positive trend will move the stock price. First back to the 80 cent range and then over $1....give it 6 months!

[Hopeforthebest]

you do realize that last quarter, profits down, operating costs up and research expenditures were down. That was not a good quarter even with the extra money spent on a revenue officer.  A tripple whammy in business is not fondly looked at in the business community. So you crystal ball will have to wait at least till mid 2023 before we might have 2 good quarters.